Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?
Clinical Chemistry March 7, 2023 Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett et al.
Experts in psychedelic research, drug discovery, and regulation discuss the challenges of clinical adoption of psychedelic compounds and their impact on laboratory medicine. FDA approval of psychedelics like psilocybin, which has Phase III trials for major depressive disorder and treatment-resistant depression, would be a major milestone. Approval would require federal workplace drug testing guidelines to address new prescription drugs, potential false positives, and Medical Review Officer decisions. Laboratories must adapt by evaluating test panels, analytical ranges, and interpretive comments. Media portrayal ranges from dangerous drugs to panaceas, but regulatory decisions should rely on objective scientific data. Patients with mood and substance use disorders stand to benefit most.